BIO.News Newsletter

A busy Friday: CMS released its timeline for penalizing drug price increases, BIO submitted comments on the importance of IP, and experts highlight RSV vaccine development and the fungal crisis. (826 words, 4 minutes, 7 seconds)

Recapping yesterday’s hearing on the federal COVID-19 response as well as what we learned about the future of clinical trials at the BIO CEO and Investor Conference. (742 words, 3 minutes, 42 seconds)

We recap what Biden said (or didn’t say) about biotech in the State of the Union, and Day 2 of the BIO CEO and Investor Conference, where drug price controls put a damper on an otherwise optimistic outlook. (663 words, 3 minutes, 18 seconds)

Day 1 of the BIO CEO and Investor Conference brought optimism about the industry and the market outlook—and a look at a new program that will ignite innovation. We tell you how to follow Day 2 and more below. (640 words, 2 minutes, 12 seconds)

Greetings from the BIO CEO and Investor Conference in New York! BIO’s new report on the state of pain and addiction shows a dire need for investment—we have more details. Last week, BIO responded to the Biden administration’s RFI on biotech regulation, explaining how technology can stimulate the economy and further big societal goals. (655 words, 3 minutes, 16 seconds)

Ending the week with what BIO experts are watching in Washington during 2023 on both health care policy and agricultural and environmental policy. We look forward to seeing you next week in New York, where we’ll be bringing you coverage of the BIO CEO & Investor Conference—it’s not too late to register! (640 words, 3 minutes, 12 seconds)

It’s all about IP, with the World Health Organization (WHO) suggesting more IP waivers in future pandemics and BIO submitting comments to USTR on global threats to IP. Plus, we recap what was said at yesterday’s Farm Bill hearing about Mexico’s corn ban. (734 words, 3 minutes, 40 seconds)

It’s been a busy week at BIO. Today, a positive court decision regarding 340B, a recap of BIO’s clinical trial diversity roundtable, and how you can weigh in on the impact of the Inflation Reduction Act’s drug pricing provisions. (794 words, 3 minutes, 58 seconds)

A feat for vaccines, the COVID-19 public health emergency in the U.S. will end on May 11. We look back at how we got here. Plus, the CEO of one of the world’s largest fertilizer companies warns of a food crisis, but biotech is advancing solutions. (612 words, 3 minutes, 3 seconds)

Drug pricing is expected to be a hot topic in 2023—here’s what you need to know about the outlook and the importance of messaging. Plus, a new strain of a deadly pig disease highlights the importance of advancing animal biotech like gene editing. (618 words, 3 minutes, 5 seconds)